2016

raphs to document changes over time with A. vera-based topical treatment. Results: The patient refused biopsy of her lesion and traditional treatments and, instead, initiated using A. vera eye drops 3 times daily. At follow-up visits, the lesion was noted to regress until it finally resolved 3 months after commencing treatment. No additional topical medications were used, and she has remained tumor free for 6 years. Conclusions: Ongoing research is warranted because A. vera may represent a new therapeutic class of medications for OSSN treatment....

Abstract Dipyridamole was introduced decades ago as a treatment for angina, subsequently found to inhibit platelet aggregation. It is most commonly used, and approved for use in thromboembolism prevention, following surgery. Some of its recognized effects such as adenosine uptake inhibition, elevation of cAMP and cGMP levels, vasodilation, and tissue perfusion are important in various ocular disorders. For this reason, dipyridamole represents an interesting candidate as a therapeutic target for the treatment of eye disorders affecting different ocular structures. The aim of this article is to review the evidence and current understanding of the mechanisms by which dipyridamole exerts its effects on different ocular tissues, discuss the role of dipyridamole in clinical practice, and highlight areas of use and routes of administration.

Realnatural, Inc. P.O. Box 6436 Los Osos, CA 93412

Researchers have used personalized proteomics to devise a successful treatment strategy for a patient with uveitis, a potentially blinding eye disease that can have many causes, making it particularly difficult to diagnose and treat effectively.

Patient-reported results of a novel treatment for pterygium and pinguecula, a common incurable eye condition presented at ARVO's Israel Chapter national meeting. The treatment utilizes the well-known cardiovascular drug dipyridamole in eye drop form. Dipyridamole has been in clinical use for 55 years, and is now being repurposed for treating intractable eye conditions such as pterygium, pinguecula and severe dry eye.

When he was 9, Mason Two Crow learned he could be legally blind before he turned 18. A few years later, his doctors told him something else:...

When he was 9, Mason Two Crow learned he could be legally blind before he turned 18. A few years later, his doctors told him something else:...

Dr. Kelly was selected based on her outstanding abstract on binocular treatment for amblyopia (‘lazy eye’).

Your Advanced Applications, Our Leading Technology. Working Together for the Best Results in Microcurrent!

In this interview, Dr. Wunsch, a world class expert on photobiology, shares the hidden dangers of LED lighting that most people are completely unaware of.

Whether or not cannabis use may increase the risk for depression and/or anxiety is not clear. For one thing, it has not been possible to draw a defini…

Natural light surrounds us. Yet not getting enough of the right forms of natural light causes disease.

NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild.

The Scientist offers independent, award-winning science journalism, covering the latest life science research, insights, and innovations.

MicroRNAs from plants accumulate in mammalian blood and tissues, where they can regulate gene expression.

The Scientist offers independent, award-winning science journalism, covering the latest life science research, insights, and innovations.

Bits of the transcriptome once believed to function as RNA molecules are in fact translated into small proteins.

Connective tissue is the most abundant type of tissue in our body. The shape and form of the body, including its organs, muscles, bones, and cartilage, are determined by the properties of connective t...

Purpose. This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and...